Last Price
1.68
Today's Change
-0.14 (7.69%)
Day's Change
1.66 - 1.83
Trading Volume
288,545
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Stephan Jackman Mr. Stephan Jackman
Full Time Employees: 4 4
IPO Date: 2021-06-15 2021-06-15
CIK: 0001677077 0001677077
ISIN: US02262M4078 US02262M4078
CUSIP: 02262M308 02262M308
Beta: -0.01 -0.01
Last Dividend: 0.00 0.00
Dcf Diff: 1.62 1.62
Dcf: 0.11 0.11
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.